Last Week Of Fun In The Markets? Click to watch.

$10.56 (-3.39%)

Volume: 864.536k

Closed: Jun 30, 2022

Hollow Logo Score: -2.838

FibroGen Stock Forecast

$10.56 (-3.39%)

Volume: 864.536k

Closed: Jun 30, 2022

Score Hollow Logo -2.838

FibroGen Company Profile

409 Illinois Street

San Francisco CA 94158


Industry: Biotechnology

Sector: Healthcare



FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing roxadustat, or FG-4592, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Top Fintech Company featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE